MyoKardia Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- MyoKardia's estimated annual revenue is currently $33.6M per year.
- MyoKardia received $Undisclosed in venture funding in August 2017.
- MyoKardia's estimated revenue per employee is $102,939
- MyoKardia's total funding is $114.4M.
- MyoKardia has 326 Employees.
- MyoKardia grew their employee count by 33% last year.
- MyoKardia currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
|Advanced Cell D...||$28.7M||185||8%||N/A||-||N/A|
|The J. Craig Ve...||$39.4M||254||N/A||N/A||-||N/A|
What Is MyoKardia?
Our Mission: Change the world for patients with cardiovascular disease through bold and innovative science. MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Our initial focus: treatment of heritable cardiomyopathies, a group of genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. We are a growing community of employees who enjoy working with and learning from each other. We collaborate in a way that ensures the growth of the company as well each employee individually. MyoKardia is committed to creating a culture that's centered on our core values. We seek individuals who not only offer expertise in their respective fields, but can serve as cultural leaders and role models for our values. Apply: http://myokardia.com/careersOpp.php Learn More: http://myokardia.com/keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the presentation ...
MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Patients.
Durability of Mavacamten's Safety and Efficacy Profile Demonstrated through Nine Months in this Study of Patients with Symptomatic, ...
|2017-08-09||$Undisclosed||Undisclosed||J.P. Morgan Securities LLC||Article|
MyoKardia Executive Hires
|2013-01-31||Jonathan Fox||Chief Medical Officer||Article|
|2013-10-31||Tassos Gianakakos||Chief Executive Officer||Article|
|2018-01-22||Cynthia Ladd||General Counsel||Article|
|2019-01-24||William Fairey||EVP/Chief Commercial Officer||Article|